These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 31879981)

  • 1. Engineering Secretory Amyloids for Remote and Highly Selective Destruction of Metastatic Foci.
    Céspedes MV; Cano-Garrido O; Álamo P; Sala R; Gallardo A; Serna N; Falgàs A; Voltà-Durán E; Casanova I; Sánchez-Chardi A; López-Laguna H; Sánchez-García L; Sánchez JM; Unzueta U; Vázquez E; Mangues R; Villaverde A
    Adv Mater; 2020 Feb; 32(7):e1907348. PubMed ID: 31879981
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering tumor cell targeting in nanoscale amyloidal materials.
    Unzueta U; Seras-Franzoso J; Céspedes MV; Saccardo P; Cortés F; Rueda F; Garcia-Fruitós E; Ferrer-Miralles N; Mangues R; Vázquez E; Villaverde A
    Nanotechnology; 2017 Jan; 28(1):015102. PubMed ID: 27893441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering a Nanostructured Nucleolin-Binding Peptide for Intracellular Drug Delivery in Triple-Negative Breast Cancer Stem Cells.
    Pesarrodona M; Sánchez-García L; Seras-Franzoso J; Sánchez-Chardi A; Baltá-Foix R; Cámara-Sánchez P; Gener P; Jara JJ; Pulido D; Serna N; Schwartz S; Royo M; Villaverde A; Abasolo I; Vazquez E
    ACS Appl Mater Interfaces; 2020 Feb; 12(5):5381-5388. PubMed ID: 31840972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Release of targeted protein nanoparticles from functional bacterial amyloids: A death star-like approach.
    Unzueta U; Cespedes MV; Sala R; Alamo P; Sánchez-Chardi A; Pesarrodona M; Sánchez-García L; Cano-Garrido O; Villaverde A; Vázquez E; Mangues R; Seras-Franzoso J
    J Control Release; 2018 Jun; 279():29-39. PubMed ID: 29641987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GSDMD-dependent pyroptotic induction by a multivalent CXCR4-targeted nanotoxin blocks colorectal cancer metastases.
    Sala R; Rioja-Blanco E; Serna N; Sánchez-García L; Álamo P; Alba-Castellón L; Casanova I; López-Pousa A; Unzueta U; Céspedes MV; Vázquez E; Villaverde A; Mangues R
    Drug Deliv; 2022 Dec; 29(1):1384-1397. PubMed ID: 35532120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bacterial mimetics of endocrine secretory granules as immobilized in vivo depots for functional protein drugs.
    Céspedes MV; Fernández Y; Unzueta U; Mendoza R; Seras-Franzoso J; Sánchez-Chardi A; Álamo P; Toledo-Rubio V; Ferrer-Miralles N; Vázquez E; Schwartz S; Abasolo I; Corchero JL; Mangues R; Villaverde A
    Sci Rep; 2016 Oct; 6():35765. PubMed ID: 27775083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Self-assembling toxin-based nanoparticles as self-delivered antitumoral drugs.
    Sánchez-García L; Serna N; Álamo P; Sala R; Céspedes MV; Roldan M; Sánchez-Chardi A; Unzueta U; Casanova I; Mangues R; Vázquez E; Villaverde A
    J Control Release; 2018 Mar; 274():81-92. PubMed ID: 29408658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supramolecular organization of protein-releasing functional amyloids solved in bacterial inclusion bodies.
    Cano-Garrido O; Rodríguez-Carmona E; Díez-Gil C; Vázquez E; Elizondo E; Cubarsi R; Seras-Franzoso J; Corchero JL; Rinas U; Ratera I; Ventosa N; Veciana J; Villaverde A; García-Fruitós E
    Acta Biomater; 2013 Apr; 9(4):6134-42. PubMed ID: 23220450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective delivery of T22-PE24-H6 to CXCR4
    Falgàs A; Pallarès V; Serna N; Sánchez-García L; Sierra J; Gallardo A; Alba-Castellón L; Álamo P; Unzueta U; Villaverde A; Vázquez E; Mangues R; Casanova I
    Theranostics; 2020; 10(12):5169-5180. PubMed ID: 32373205
    [No Abstract]   [Full Text] [Related]  

  • 10. Selective depletion of metastatic stem cells as therapy for human colorectal cancer.
    Céspedes MV; Unzueta U; Aviñó A; Gallardo A; Álamo P; Sala R; Sánchez-Chardi A; Casanova I; Mangues MA; Lopez-Pousa A; Eritja R; Villaverde A; Vázquez E; Mangues R
    EMBO Mol Med; 2018 Oct; 10(10):. PubMed ID: 30190334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Collaborative membrane activity and receptor-dependent tumor cell targeting for precise nanoparticle delivery in CXCR4
    Sala R; Sánchez-García L; Serna N; Céspedes MV; Casanova I; Roldán M; Sánchez-Chardi A; Unzueta U; Vázquez E; Mangues R; Villaverde A
    Acta Biomater; 2019 Nov; 99():426-432. PubMed ID: 31494293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bacterial inclusion bodies are industrially exploitable amyloids.
    de Marco A; Ferrer-Miralles N; Garcia-Fruitós E; Mitraki A; Peternel S; Rinas U; Trujillo-Roldán MA; Valdez-Cruz NA; Vázquez E; Villaverde A
    FEMS Microbiol Rev; 2019 Jan; 43(1):53-72. PubMed ID: 30357330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacterial inclusion bodies: an emerging platform for drug delivery and cell therapy.
    Villaverde A
    Nanomedicine (Lond); 2012 Sep; 7(9):1277-9. PubMed ID: 22994952
    [No Abstract]   [Full Text] [Related]  

  • 14. Receptor and Microenvironment Dual-Recognizable Nanogel for Targeted Chemotherapy of Highly Metastatic Malignancy.
    Chen J; Ding J; Xu W; Sun T; Xiao H; Zhuang X; Chen X
    Nano Lett; 2017 Jul; 17(7):4526-4533. PubMed ID: 28644032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and functional features of self-assembling protein nanoparticles produced in endotoxin-free Escherichia coli.
    Rueda F; Céspedes MV; Sánchez-Chardi A; Seras-Franzoso J; Pesarrodona M; Ferrer-Miralles N; Vázquez E; Rinas U; Unzueta U; Mamat U; Mangues R; García-Fruitós E; Villaverde A
    Microb Cell Fact; 2016 Apr; 15():59. PubMed ID: 27059706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bacterial Inclusion Bodies: Discovering Their Better Half.
    Rinas U; Garcia-Fruitós E; Corchero JL; Vázquez E; Seras-Franzoso J; Villaverde A
    Trends Biochem Sci; 2017 Sep; 42(9):726-737. PubMed ID: 28254353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin-loaded functionalized selenium nanoparticles for enhanced antitumor efficacy in cervical carcinoma therapy.
    Xia Y; Xiao M; Zhao M; Xu T; Guo M; Wang C; Li Y; Zhu B; Liu H
    Mater Sci Eng C Mater Biol Appl; 2020 Jan; 106():110100. PubMed ID: 31753388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanostructured toxins for the selective destruction of drug-resistant human CXCR4
    Serna N; Álamo P; Ramesh P; Vinokurova D; Sánchez-García L; Unzueta U; Gallardo A; Céspedes MV; Vázquez E; Villaverde A; Mangues R; Medema JP
    J Control Release; 2020 Apr; 320():96-104. PubMed ID: 31931052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone disease.
    Vanderburgh JP; Kwakwa KA; Werfel TA; Merkel AR; Gupta MK; Johnson RW; Guelcher SA; Duvall CL; Rhoades JA
    J Control Release; 2019 Oct; 311-312():257-272. PubMed ID: 31494183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-Assembled Nanoparticles Based on Amphiphilic Anticancer Drug-Phospholipid Complex for Targeted Drug Delivery and Intracellular Dual-Controlled Release.
    Li Y; Lin J; Yang X; Li Y; Wu S; Huang Y; Ye S; Xie L; Dai L; Hou Z
    ACS Appl Mater Interfaces; 2015 Aug; 7(32):17573-81. PubMed ID: 26234408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.